Avatrombopag (Doptelet): Oral TPO-RA for Multiple Thrombocytopenia Types

Avatrombopag (brand name: Doptelet) is an oral thrombopoietin receptor agonist (TPO-RA) that stimulates megakaryocyte proliferation and maturation in the bone marrow to increase platelet production. Approved in multiple countries and regions, it is widely used for specific types of thrombocytopenia.

1. Chronic Liver Disease-Associated Thrombocytopenia​

For adult patients with chronic liver disease who require diagnostic procedures or surgery and have thrombocytopenia, avatrombopag can be used preoperatively to raise platelet levels, reducing risks associated with low platelet counts and facilitating smooth procedural execution.

2. Chronic Immune Thrombocytopenia (ITP) in Adults​

Avatrombopag is also indicated for adult patients with chronic ITP who have had inadequate responses to prior therapies. For those whose platelet levels remain unstable after conventional treatment, this drug helps the body generate more platelets, offering a new option for long-term disease management.

3. Pediatric Indication Expansion​

Based on completed clinical studies, avatrombopag is now approved for children aged 1 year and older with persistent or chronic ITP, particularly those with insufficient response to previous treatments. This expansion extends the drug’s utility from adults to eligible pediatric patients, benefiting a broader age range.

Avatrombopag does not involve platelet transfusion; instead, it activates the thrombopoietin receptor to stimulate endogenous platelet production, addressing thrombocytopenia mechanistically. Overall, it has become a key oral agent for chronic liver disease-related thrombocytopenia and chronic ITP, holding significant clinical value in hematology.